Drug Trial Radar · NCT07358546
A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Mar 13, 2026
Primary completion
Oct 13, 2027
Study completion Oct 13, 2027
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jan 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to study the pharmacokinetic (PK) and safety profiles of a single dose of efimosfermin alfa in participants with varying degrees of Hepatic Impairment (HI) (assessed by Child-Pugh score) due to steatotic liver disease, with and without significant alcohol consumption.
Conditions
- Non-alcoholic Fatty Liver Disease
Interventions
Efimosfermin alfaDrug
Efimosfermin alfa to be administrated subcutaneously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the serum drug concentration versus time curve from time zero to infinity (AUC[0-inf]) of efimosfermin alfaTime frame: Up to 90 Days
- Maximum observed serum drug concentration (Cmax) of efimosfermin alfaTime frame: Up to 90 Days
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Rialto, California · Recruiting
GSK Investigational Site
Miami Lakes, Florida · Recruiting
GSK Investigational Site
Tampa, Florida · Recruiting
GSK Investigational Site
Houston, Texas · Recruiting
GSK Investigational Site
San Antonio, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.